| AJCC | American Joint Committee on Cancer |
| ALT | alanine aminotransferase |
| AST | aspartate aminotransferase |
| CI | confidence interval |
| CRP | C-reactive protein |
| CTCAE | Common Terminology Criteria for Adverse Events |
| CTLA-4 | cytotoxic T-lymphocyte-associated protein-4 |
| CXCL | chemokine (C-X-C motif) ligand |
| ECOG | Eastern Cooperative Oncology |
| HR | hazard ratio |
| ICI | immune checkpoint inhibition |
| IQR | interquartile range |
| irAE | immune-related adverse events |
| LDH | lactate dehydrogenase |
| LoD | limit of detection |
| NA | Not applicable |
| NLR | neutrophil-to-lymphocyte ratio |
| OS | overall survival |
| PD | progressive disease |
| PD-1 | programmed cell death protein-1 |
| PFS | progression-free survival |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| SD | standard deviation |
| SITC | Society for Immunotherapy of Cancer |
| Th | T-helper lymphocytes |
| TNF-α | tumor necrosis factor alpha |